Veru

Veru reported an adjusted loss of $0.30 per share for the third quarter, beating the consensus estimate of $0.31. Net loss levels improved versus the prior period, supported by a reduced share count and lower administrative expenses, while R&D spending for the PLATEAU study increased. The phase IIb PLATEAU study is fully enrolled with 239 patients; an interim analysis is expected in Q1 2027, and current cash of $23.9 million should fund operations beyond that readout. The company remains unprofitable and continues to depend on future clinical results and potential partnerships. » More on de.investing.com

Veru has completed recruitment of 239 participants for the PLATEAU study, which is evaluating enobosarm (3 mg) in combination with semaglutide in older adults with obesity. The primary endpoint is percent weight change at 68 weeks; an interim analysis of fat and lean mass is planned for Q1 2027, with top‑line data expected in Q4 2027. The US Patent Office has issued a notice of allowance for the combination therapy, with protection expected after grant through at least October 3, 2044. In Q3 of fiscal 2026 Veru reported a net loss of USD 7.0 million and cash and cash equivalents of USD 23.9 million. » More on de.investing.com

Veru will publish on August 10, 2026 the results for the quarter ended June 30, 2026. On average, 2 analysts expect a loss of $0.320 per share (prior year: $0.500) on expected revenue of $0.0 million. For the current fiscal year, the same analysts forecast an average loss of $1.015 per share and revenue of $0.0 million. » More on finanzen.net